Recently, Lealing Biopharma (Suzhou) Co., Ltd. (“Lealing Bio”) announced the completion of an angel round financing worth tens of millions of RMB, co-invested by Bohe Angel Fund and Yuanbio Venture Capital. The raised funds will primarily be used to enhance the TCR technology platform, advance related project pipelines, and strengthen team development.
